Gilead Science的股票略有下降,但比预期的收入低,保持了“机动购买”评级。 Gilead Sciences' stock slightly drops but beats earnings expectations, maintaining a "Moderate Buy" rating.

Gilead Sciences是一家生物制药公司,其股份被Sicart Associates和KBC Group NV等主要投资者略有减少。 Gilead Sciences, a biopharmaceutical company, saw its shares slightly reduced by major investors like Sicart Associates and KBC Group NV. 尽管收入略有下降,但Gilead报告说,每股收入为1.81美元,比分析师的预期值低。 Despite a minor drop in revenue, Gilead reported earnings of $1.81 per share, beating analysts' expectations. 该公司以艾滋病毒/艾滋病和肝炎治疗闻名,公认评级为“机动购买”,价格目标为110.55美元。 The company, known for HIV/AIDS and hepatitis treatments, has a consensus rating of "Moderate Buy" with a price target of $110.55. Gilead的股价目前为110.67美元,股息收益为2.86%。 Gilead's stock is currently at $110.67, with a 2.86% dividend yield.